

THE GLOBAL BLOOD INDUSTRY



HLC008H
June 2013

Melissa Elder
Project Analyst

ISBN: 1-56965-433-6

bcc | Research
Market Forecasting

BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481
866-285-7215, 781-489-7301
www.bccresearch.com
Custom Reports:
carol.laverty@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOAL AND OBJECTIVES	2
REASONS FOR DOING THIS STUDY	2
CONTRIBUTION OF THE STUDY AND INTENDED AUDIENCE	2
SCOPE AND FORMAT	3
METHODOLOGY AND INFORMATION SOURCES	3
ANALYST'S CREDENTIALS	3
RELATED BCC REPORTS	4
BCC ON-LINE SERVICES	4
DISCLAIMER	4
CHAPTER 2 SUMMARY	6
MAJOR FINDINGS	6
<i>SUMMARY TABLE GLOBAL MARKET FOR BLOOD PRODUCTS, THROUGH 2017 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE GLOBAL MARKET FOR BLOOD PRODUCTS, 2010-2017 (\$ MILLIONS)</i>	7
CHAPTER 3 OVERVIEW	9
THE BLOOD INDUSTRY	9
BLOOD INDUSTRY TERMS AND ABBREVIATIONS[1]	9
HISTORY OF THE BLOOD INDUSTRY	12
<i>TABLE 1 TIMELINE OF THE BLOOD INDUSTRY</i>	13
BLOOD AND ITS COMPONENTS	14
PLASMA	15
<i>TABLE 2 COMPOSITION OF BLOOD</i>	16
CELLULAR ELEMENTS	16
Red and White Blood Cells	16
Platelets	17
IMMUNOGLOBULIN PRODUCTS	17
THE DANGERS OF TRANSFUSED BLOOD	17
TRANSFUSION ASSOCIATED RISKS	18
Diseases Contracted from Blood Transfusions and Related Identification Testing	18
<i>TABLE 3 MAJOR DISEASES CONTRACTED FROM BLOOD TRANSFUSIONS, U.S. ANALYSIS</i>	18
HIV/AIDS	20
<i>TABLE 4 CBER LICENSED HIV DONOR SCREENING TESTS (LAST UPDATED JANUARY 17, 2013)</i>	21
Hepatitis A	22
Hepatitis B	22
<i>TABLE 5 CBER LICENSED SCREENING TESTS FOR HEPATITIS B (LAST UPDATED JANUARY 17, 2013)</i>	23
Hepatitis C	23
<i>TABLE 6 CBER LICENSED SCREENING TESTS FOR HEPATITIS C (LAST UPDATED JANUARY 17, 2013)</i>	24
Hepatitis D	24

TOPIC	PAGE NO.
Hepatitis E	25
Human T-Cell Lymphotropic Virus-(HTLV-I, -II)	25
<i>TABLE 7 CBER LICENSED SCREENING TESTS FOR HTLV-I AND HTLV-II (LAST UPDATED JANUARY 17, 2013)</i>	26
Cytomegalovirus	26
<i>TABLE 8 CBER LICENSED SCREENING TESTS FOR CMV (LAST UPDATED JANUARY 17, 2013)</i>	27
West Nile Virus	27
<i>TABLE 9 CBER LICENSED SCREENING TESTS FOR WEST NILE (LAST UPDATED JANUARY 17, 2013)</i>	28
"Mad Cow Disease"-Creutzfeldt-Jakob Disease (CJD)	28
Syphilis	29
<i>TABLE 10 CBER LICENSED SCREENING TESTS FOR SYPHILIS (LAST UPDATED JANUARY 17, 2013)</i>	29
Chagas Disease	29
Chlamydia Trachomatis	31
<i>TABLE 11 CBER LICENSED SCREENING TESTS FOR CHLAMYDIA (LAST UPDATED JANUARY 17, 2013)</i>	32
Neisseria Gonorrhea	32
<i>TABLE 12 CBER LICENSED SCREENING TESTS FOR GONORRHEA (LAST UPDATED JANUARY 17, 2013)</i>	33
EFFORTS TO CREATE A VIRUS-FREE BLOOD SUPPLY	33
Plasma Treatments	33
Trinitrobutyl Phosphate and Sodium Cholate	33
Methylene Blue-treated Plasma	33
Amatosalen HCL-Treated Plasma	34
Platelet Treatments	34
RBCs	35
NEGATIVE REACTIONS FROM BLOOD TRANSFUSIONS	35
BLOOD/PLASMA COMPONENT RISKS	36
CHAPTER 4 THE BLOOD MANAGEMENT SYSTEM- BLOOD COLLECTION, PROCESSING AND USE	39
BLOOD COLLECTION	39
TYPES OF BLOOD ESTABLISHMENTS AND BLOOD FACILITIES	39
Major Facilities	39
Auxiliary Facilities	40
Transfusion Services	40
ORGANIZATIONS COLLECTING BLOOD	40
<i>TABLE 13 FDA REGISTERED BLOOD ESTABLISHMENTS BY STATE* AND POSSESSION</i>	41
For-Profit Blood Collection	43
Plasma Collection Centers	43
National Donor Deferral Registry	43
Non-Profit Blood Collection	43
American Red Cross	44
Community Blood Banks	44
Hospitals	44
Other Blood Collection Sites	45

TOPIC	PAGE NO.
BLOOD DONATION DEMOGRAPHICS	45
Global Demographic Trends	45
<i>TABLE 14 ESTIMATED GLOBAL POPULATION AND GROWTH RATE BY SELECTED AGE GROUP AND SELECTED YEARS, THROUGH 2030 (MILLIONS)</i>	46
<i>FIGURE 1 ESTIMATED GLOBAL POPULATION BY SELECTED AGE GROUP AND SELECTED YEARS, 2000-2030 (MILLIONS)</i>	46
<i>TABLE 15 GLOBAL POPULATION BY SELECTED COUNTRY, THROUGH 2015 (MILLIONS)</i>	47
<i>FIGURE 2 GLOBAL POPULATION BY SELECTED COUNTRY, 2010 AND 2015 (MILLIONS)</i>	47
DONOR RECRUITMENT AND REGULATIONS	47
BLOOD SCREENING AND EVALUATION	48
METHODS FOR COLLECTING BLOOD FROM A DONOR	48
Manual Collection	48
Automated Collection	49
Plasmapheresis	49
Plateletpheresis	50
Leukopheresis	50
Red Blood Cell Apheresis	50
PLASMA COLLECTION	50
Commercial Nature of Plasmapheresis	51
Global Nature of the Plasma Industry	51
Plasma Fractionators	51
Distributors/Brokers	52
BLOOD TYPING AND TESTING FOR DISEASES	52
Blood Typing	52
<i>TABLE 16 TESTS ROUTINELY PERFORMED ON BLOOD DONATIONS</i>	53
<i>TABLE 17 BLOOD TYPE ANTIGEN/ANTIBODY REACTIONS</i>	54
Methods of Typing	54
Manual Blood Typing Methods	54
Slide/Tile Testing	54
Tube Testing	54
Microplate	55
Automated Blood Typing and Screening Methods	55
Blood Testing	55
Blood Storage	56
BLOOD PROCESSING	56
Preparation and Use of the Components	56
Red Blood Cell Components	56
Platelets	56
Plasma	57
BLOOD TRANSFUSIONS	57
Transfusion in the U.S.	57
Testing before Transfusion	57
Manual Cross-Match Techniques	57
Major Cross-Match	57
Minor Cross-Match	58
Antibody Screen	58

TOPIC	PAGE NO.
Coombs Test	58
TYPES OF TRANSFUSIONS	58
Whole Blood	58
Packed Red Blood Cells	59
Platelets	59
Leukocytes	60
Fresh Frozen Plasma (FFP)	60
<i>TABLE 18 SELECTED USES OF FFP</i>	60
Cryoprecipitate	61
Coagulation Factors	61
<i>TABLE 19 LISTING OF BLOOD PRODUCTS FOR THERAPEUTIC USE</i>	61
Immune Serum Globulin/IMIG/IGIV	62
Factor VIII	62
Factor IX and Factor IX Complex	62
Factor VIIa	63
Fibrin/Thrombin	63
Therapeutic Apheresis	63
BLOOD MANAGEMENT ISSUES	63
AVAILABILITY ISSUES	63
BLOODLESS SURGERY	64
Bloodless Medicine and Surgery Hospital Directory	64
SAFETY ISSUES: RISK MANAGEMENT	71
<i>TABLE 20 FACTORS TO REDUCE RISKS OF TRANSFUSION- ASSOCIATED DISEASES</i>	71
Better Donor Screening	72
Better Viral Screening Tests	72
Get More Repeat Donors	72
Develop Better Viral Inactivation Processes	72
Selective Use of Blood Derivative Products	72
BLOOD TRANSFUSION FATALITIES	73
<i>TABLE 21 TRANSFUSION-RELATED FATALITIES BY COMPLICATION, FY 2008-FY 2012</i>	73
<i>TABLE 22 FATALITIES NOT RELATED TO TRANSFUSION OR TRANSFUSION NOT RULED OUT, FY2008-FY2012</i>	74
<i>TABLE 23 POST-DONATION "NOT RULED OUT" FATALITY REPORTS BY DONATED PRODUCT, FY2008 THROUGH FY2012</i>	74
CHAPTER 5 REGULATION OF THE BLOOD BUSINESS	76
REGULATION OF THE U.S. BLOOD BUSINESS	76
<i>TABLE 24 FEDERAL ORGANIZATIONS RESPONSIBLE FOR U.S. BLOOD SAFETY</i>	76
STATUTORY AUTHORITY OF THE FDA	77
Center for Biologics Evaluation and Research	77
chapter Office of Regulatory Affairs (ORA)	77
Office of Biologics, The Division of Blood and Blood Products	78
<i>TABLE 25 FDA AUTHORITY IN REGULATING BLOOD BANKING AND BLOOD PRODUCTS</i>	79
THE MAJOR REGULATIONS AND POLICY MATTERS CONCERNING THE U.S. BLOOD SUPPLY	79
The Clinical Laboratory Improvement Act of 1988 (CLIA)	79
The FDA'S Five Layers	80

TOPIC	PAGE NO.
Donor Screening	80
Blood Testing	80
Donor Deferral Lists	81
Quarantine	81
Problems and Deficiencies	81
The FDA Blood Action Plan	81
Team Biologics	81
Fuel, Phone Excise Taxes	82
HOW REGULATIONS GET IMPLEMENTED	82
Inspecting Blood Banks and Plasma Collection Facilities	82
<i>TABLE 26 MAJOR AREAS OF CONCERN FOR INSPECTING BLOOD FACILITIES</i>	83
OTHER ORGANIZATIONS INVOLVED IN BLOOD REGULATION	83
National Heart, Lung, and Blood Institute (NHLBI)	83
Blood Diseases and Resources Program	84
Occupational Safety and Health Administration (OSHA)	85
Health Care Financing Administration (HCFA)	85
The Department of Defense	85
State Regulatory Agencies	86
VOLUNTARY REGULATION BY PROFESSIONAL AND TRADE ASSOCIATIONS	86
American Association of Blood Banks	86
PPTA: Plasma Protein Therapeutics Association	87
America's Blood Centers (ABC)	88
THE EUROPEAN UNION (EU) BLOOD DIRECTIVE	88
The International Society for Blood Transfusion - ISBT 128	88
THE FUTURE OF BLOOD REGULATION	89
CHAPTER 6 THE GLOBAL BLOOD AND BLOOD PRODUCTS MARKET OVERVIEW	91
DRIVING FORCES OF THE INDUSTRY	91
<i>FIGURE 3 VARIABLES INFLUENCING THE DYNAMICS OF DEMAND FOR BLOOD FOR TRANSFUSION</i>	91
MARKET SUMMARY	92
<i>FIGURE 4 BLOOD MARKET COST AND PRICING ANALYSIS</i>	92
PRICING OF BLOOD	93
<i>TABLE 27 ESTIMATED U.S. COST OF BLOOD COMPONENTS, THROUGH 2012 (\$)</i>	94
National Blood Exchange (NBE)	94
RBCs and Leuko-reduced RBCs	95
Platelets	95
Random Donor Platelets	95
Fresh Frozen Plasma (FFP)	95
Cryoprecipitate	96
Washed Cells	96
Deglycerolized Cells	96
Granulocytes	96
Gamma-Irradiated Blood	96
PATTERNS OF TRANSFUSION PROCEDURES	96
Leuko-reduction	97
Impact of Autologous Donations	97
Types of Autologous Transfusions	98

TOPIC	PAGE NO.
Risks of PABD	99
CHAPTER 7 BLOOD INDUSTRY ANALYSIS	101
GLOBAL MARKETS FOR WHOLE BLOOD COLLECTIONS	101
LOCAL EFFORTS AND IMPROVEMENTS	101
Africa	102
South Africa	102
Asia	103
China	103
India	103
Japan	104
Pakistan	104
Islamic Republic of Iran	104
Sri Lanka	104
Vietnam	104
Europe	105
Britain	105
France	105
Germany	105
Russia	105
Netherlands	106
Switzerland	106
Turkey	106
North America and Caribbean	106
Canada	106
Haiti	107
Oceania Region	107
Australia	107
New Zealand	107
Cook Islands	107
South America	107
Argentina	107
Bolivia	108
Brazil	108
U.S. BLOOD COLLECTION DATA	108
<i>TABLE 28 U.S. BLOOD COLLECTION AND TRANSFUSION DATA, THROUGH 2017 (MILLION UNITS/PINTS)</i>	109
<i>FIGURE 5 U.S. BLOOD COLLECTION AND TRANSFUSION DATA, 2007-2017 (MILLION UNITS/PINTS)</i>	109
GLOBAL MARKETS FOR SOURCE PLASMA COLLECTIONS	110
<i>TABLE 29 PLASMA COLLECTIONS FOR THE U.S. AND OTHER MARKETS, THROUGH 2017 (\$ BILLIONS, MILLIONS ML)</i>	110
<i>FIGURE 6 PLASMA COLLECTIONS FOR THE U.S. AND OTHER MARKETS, 2010-2017 (MILLION ML)</i>	110
GLOBAL MARKETS FOR BLOOD THERAPEUTICS	111
<i>TABLE 30 PLASMA PRODUCTS MARKET FOR THE U.S. AND OTHER MARKETS,* THROUGH 2017 (\$ BILLIONS)</i>	111
<i>FIGURE 7 PLASMA PRODUCTS MARKET FOR THE U.S. AND OTHER MARKETS,* 2010-2017 (\$ BILLIONS)</i>	111

TOPIC	PAGE NO.
PLASMA AND PLASMA-DERIVED PRODUCTS	112
Plasma Therapeutic Products	112
<i>TABLE 31 GLOBAL MARKET SIZE OF PLASMA THERAPEUTIC DERIVATIVES BY TYPE, THROUGH 2017 (\$ MILLIONS)</i>	112
<i>FIGURE 8 GLOBAL MARKET SIZE OF PLASMA THERAPEUTIC DERIVATIVES BY TYPE, 2010-2017 (MILLIONS)</i>	112
ALBUMIN AND PLASMA PROTEIN FRACTION (PPF)	113
FDA Notification Regarding Safety of Albumin Administration in the Critically Ill	114
Recombinant Human Albumin	114
Albumin Market Dynamics	114
<i>TABLE 32 CURRENTLY MARKETED ALBUMIN AND PLASMA PROTEIN FRACTION (PPF) PRODUCTS (%)</i>	115
Albumin and PPF Market Size	116
<i>TABLE 33 GLOBAL MARKET FOR HUMAN SERUM ALBUMIN AND PPF BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	116
<i>FIGURE 9 GLOBAL MARKET FOR HUMAN SERUM ALBUMIN AND PPF BY REGION, 2010-2017 (MILLIONS)</i>	116
Albumin and PPF Market Trends	117
CLOTTING FACTORS	118
<i>TABLE 34 EXAMPLES OF COMMON BLOOD CLOTTING FACTORS</i>	118
Hemophilia	119
<i>TABLE 35 WORLDWIDE AND U.S. HEMOPHILIA STATISTICS, 2012 ESTIMATES</i>	120
Market Demand and Market Size	120
<i>TABLE 36 GLOBAL MARKET FOR PLASMA-DERIVED AND RECOMBINANT CLOTTING FACTORS, THROUGH 2017 (REVENUES IN \$ MILLIONS)</i>	120
<i>FIGURE 10 GLOBAL MARKET FOR PLASMA-DERIVED AND RECOMBINANT CLOTTING FACTORS, 2010-2017 (\$ MILLIONS)</i>	121
<i>TABLE 37 GLOBAL MARKET FOR PLASMA-DERIVED AND RECOMBINANT CLOTTING FACTORS BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	121
<i>FIGURE 11 GLOBAL MARKET FOR PLASMA-DERIVED AND RECOMBINANT CLOTTING FACTORS BY REGION, 2010-2017 (MILLIONS)</i>	121
Factor VIII	122
<i>TABLE 38 FDA APPROVED FACTOR VIII PRODUCTS</i>	122
<i>TABLE 39 GLOBAL MARKET SHARE OF FACTOR VIII COMPANIES, 2012</i>	125
<i>FIGURE 12 GLOBAL MARKET SHARE OF FACTOR VIII COMPANIES, 2012 (%)</i>	125
<i>FIGURE 13 GLOBAL MARKET SHARE OF FACTOR VIII BY HUMAN AND RECOMBINANT PRODUCTS, 2012 (%)</i>	125
Factor IX	126
<i>TABLE 40 FDA APPROVED FACTOR IX PRODUCTS</i>	126
<i>TABLE 41 GLOBAL MARKET SHARE OF FACTOR IX COMPANIES, 2012 (%/MILLIONS)</i>	127
<i>FIGURE 14 GLOBAL MARKET SHARE OF FACTOR IX COMPANIES, 2012 (%)</i>	127
Factor VIIa	127
Biosimilar Factor VIIa Development	128
<i>TABLE 42 FDA APPROVED FACTOR VII PRODUCTS</i>	128
<i>TABLE 43 GLOBAL MARKET SHARE OF FACTOR IX COMPANIES, 20121 (PERCENT/MILLIONS)</i>	129
<i>FIGURE 15 GLOBAL MARKET SHARE OF FACTOR IX COMPANIES, 2012 (%)</i>	129
Prothrombin Complex Concentrates	129
<i>TABLE 44 FDA APPROVED PROTHROMBIN COMPLEX CONCENTRATE PRODUCTS</i>	130

TOPIC	PAGE NO.
IMMUNOGLOBULINS	130
IVIG	131
<i>TABLE 45 SELECTED CONDITIONS TREATED BY IVIG</i>	131
<i>TABLE 46 FDA APPROVED IMMUNOGLOBULINS</i>	132
Hyperimmunes	133
<i>TABLE 47 FDA APPROVED HYPERIMMUNE IMMUNOGLOBULINS</i>	133
Other	135
IMIG	135
Immunoglobulin Market Size	135
<i>TABLE 48 GLOBAL MARKET FOR IMMUNOGLOBULINS, THROUGH 2017 (\$ MILLIONS)</i>	136
<i>FIGURE 16 GLOBAL MARKET FOR IMMUNOGLOBULINS, 2010-2017 (MILLIONS)</i>	136
<i>TABLE 49 GLOBAL MARKET FOR IMMUNOGLOBULINS BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	136
<i>FIGURE 17 GLOBAL MARKET FOR IMMUNOGLOBULINS BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	137
RSV	137
CMV Immunoglobulin	137
Hepatitis B Immune Globulin	138
Rho(D) Immunoglobulin	138
Tetanus Immunoglobulin (TIG)	138
Rabies Immunoglobulin	138
Varicella Immunoglobulin	139
Vaccinia Immune Globulin Intravenous (VIG)	139
Alpha-1-Proteinase Inhibitor	139
FIBRIN SEALANTS AND THROMBIN	140
<i>TABLE 50 GLOBAL MARKET FOR FIBRIN SEALANTS AND THROMBIN, THROUGH 2017 (\$ MILLIONS)</i>	140
<i>FIGURE 18 GLOBAL MARKET FOR FIBRIN SEALANTS AND THROMBIN, 2010-2017 (\$ MILLIONS)</i>	141
<i>TABLE 51 GLOBAL MARKET FOR FIBRIN SEALANTS AND THROMBIN BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	141
<i>FIGURE 19 GLOBAL MARKET FOR FIBRIN SEALANTS AND THROMBIN BY REGION, 2010-2017 (\$ MILLIONS)</i>	142
ANTITHROMBIN III	142
<i>TABLE 52 GLOBAL MARKET FOR ANTITHROMBIN, THROUGH 2017 (\$ MILLIONS)</i>	143
<i>FIGURE 20 GLOBAL MARKET FOR ANTITHROMBIN, 2010-2017 (\$ MILLIONS)</i>	143
<i>TABLE 53 GLOBAL MARKET FOR ANTITHROMBIN BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	143
<i>FIGURE 21 GLOBAL MARKET FOR ANTITHROMBIN BY REGION, 2010-2017 (\$ MILLIONS)</i>	143
GLOBAL MARKETS FOR BLOOD TYPING AND SCREENING PRODUCTS	144
<i>TABLE 54 GLOBAL MARKETS FOR BLOOD TYPING AND SCREENING PRODUCTS, THROUGH 2017 (\$ MILLIONS)</i>	144
<i>FIGURE 22 GLOBAL MARKETS FOR BLOOD TYPING AND SCREENING PRODUCTS, 2010-2017 (\$ MILLIONS)</i>	144
<i>TABLE 55 GLOBAL MARKETS FOR BLOOD TYPING AND SCREENING PRODUCTS, THROUGH 2017 (\$ MILLIONS)</i>	146
<i>FIGURE 23 GLOBAL MARKETS FOR BLOOD TYPING AND SCREENING PRODUCTS, 2010-2017 (\$ MILLIONS)</i>	146
TYPES OF TESTING	146

TOPIC	PAGE NO.
POLYMERASE CHAIN REACTION (PCR) AMPLIFICATION	147
<i>TABLE 56 SELECTED PCR DONOR SCREENING TESTS</i>	147
NUCLEIC ACID AMPLIFICATION TEST (NAT)	147
<i>TABLE 57 SELECTED NAT DONOR SCREENING TESTS</i>	148
IMMUNOASSAY	148
<i>TABLE 58 SELECTED IMMUNOASSAY DONOR SCREENING TESTS</i>	149
MARKET SIZE BLOOD TESTING PRODUCTS FOR DONOR SCREENING	150
<i>TABLE 59 THE GLOBAL BLOOD DONOR SCREENING TESTING MARKET BY TYPE OF TESTS, THROUGH 2017 (\$ MILLIONS)</i>	150
<i>FIGURE 24 GLOBAL BLOOD DONOR SCREENING TESTING MARKET BY TYPE, 2010-2017 (\$ MILLIONS)</i>	150
MARKET PARTICIPANTS DONOR SCREENING PRODUCTS	151
<i>TABLE 60 SELECTED SUPPLIERS: MAJOR DONOR SCREENING TEST AREAS</i>	151
BLOOD TYPING	152
MARKET SIZE OF BLOOD TYPING	152
<i>TABLE 61 THE GLOBAL MARKET FOR BLOOD TYPING INSTRUMENTS AND SUPPLIES BY TYPE, THROUGH 2017 (\$ MILLIONS)</i>	153
<i>FIGURE 25 THE GLOBAL MARKET FOR BLOOD TYPING INSTRUMENTS AND SUPPLIES BY TYPE, 2010-2017 (\$ MILLIONS)</i>	153
MARKET STRUCTURE AND PARTICIPANTS	153
Manual Typing Methods	154
Automated Blood Typing	154
Immucor	154
Ortho	155
Olympus	155
GLOBAL MARKETS FOR BLOOD PROCESSING EQUIPMENT AND ASSOCIATED PRODUCTS	156
<i>TABLE 62 GLOBAL MARKET FOR BLOOD COLLECTION AND PROCESSING EQUIPMENT AND CONSUMABLES, THROUGH 2017 (\$ MILLIONS)</i>	156
<i>FIGURE 26 GLOBAL MARKET FOR BLOOD COLLECTION AND PROCESSING EQUIPMENT AND CONSUMABLES, 2010-2017 (\$ MILLIONS)</i>	156
<i>TABLE 63 GLOBAL MARKET FOR BLOOD AND PLASMA COLLECTION AND TRANSFUSION PRODUCTS, THROUGH 2017 (\$ MILLIONS)</i>	158
<i>FIGURE 27 GLOBAL MARKET FOR BLOOD AND PLASMA COLLECTION AND TRANSFUSION PRODUCTS, 2010-2017 (\$ MILLIONS)</i>	158
COLLECTION PRODUCTS	158
<i>TABLE 64 GLOBAL MARKET FOR COLLECTION PRODUCTS BY TYPE, THROUGH 2017 (\$ MILLIONS)</i>	159
<i>FIGURE 28 GLOBAL MARKET FOR COLLECTION PRODUCTS BY TYPE, 2010-2017 (\$ MILLIONS)</i>	159
BLOOD AND PLASMA COLLECTION SUPPLIES	159
Plasma Collection Sets	160
Blood Bags	160
PLASMA AND BLOOD COLLECTION EQUIPMENT	160
Blood Salvage	161
Other Collection Equipment	161
MARKET PARTICIPANTS	161
Haemonetics	161
PCS2	161
Cymbal	161

TOPIC	PAGE NO.
MCS+ 8150 System	161
MCS+ 9000 System	162
Cell Saver Systems	162
OrthoPAT System	162
ACP 215 System	162
Fresenius Kabi/Fenwal, Inc.	162
Apheresis Collections	163
Autopheresis-C	163
Alyx Component Collection System	163
Amicus Separator	163
Aurora	163
Terumo BCT	163
TRANSFUSION PRODUCTS	164
<i>TABLE 65 GLOBAL MARKET FOR TRANSFUSION PRODUCTS BY TYPE, THROUGH 2017 (\$ MILLIONS)</i>	164
<i>FIGURE 29 GLOBAL MARKET FOR TRANSFUSION PRODUCTS BY TYPE, 2010-2017 (\$ MILLIONS)</i>	164
Transfusion Sets/In	165
Blood Filter Market	165
Transfusion Equipment	165
Accessories	165
CHAPTER 8 BLOOD RESEARCH AND DEVELOPMENT	167
DEDICATED BLOOD RESEARCH FACILITIES	167
JEROME H. HOLLAND LABORATORY (ARC)	167
NATIONAL BLOOD FOUNDATION (NBF)	167
CENTER FOR BLOOD RESEARCH (CBR)	167
BLOOD SUBSTITUTES	169
FIBRIN SEALANT AND GLUE	170
ALBUMIN AND IVIG TREATMENT FOR ALZHEIMER'S DISEASE	170
THE VETERINARY BLOOD MARKET	170
<i>TABLE 66 REGIONAL VETERINARY BLOOD BANKS</i>	171
CHAPTER 9 CORPORATE PROFILES	174
ABBOTT LABORATORIES	174
<i>TABLE 67 ABBOTT'S SALES HISTORY, 2010-2012 (\$ MILLIONS)</i>	175
<i>FIGURE 30 ABBOTT'S SALES HISTORY, 2010-2012 (\$ MILLIONS)</i>	175
BAXTER INTERNATIONAL, INC.	175
<i>TABLE 68 BAXTER'S SALES HISTORY, 2010-2012 (\$ MILLIONS)</i>	176
<i>FIGURE 31 BAXTER'S SALES HISTORY, 2010-2012 (\$ MILLIONS)</i>	176
BAYER AG	177
<i>TABLE 69 BAYER'S SALES HISTORY, 2010-2012 (\$ MILLIONS)</i>	177
<i>FIGURE 32 BAYER'S SALES HISTORY, 2010-2012 (\$ MILLIONS)</i>	177
BIO-RAD LABORATORIES, INC.	178
<i>TABLE 70 BIO-RAD'S SALES HISTORY, 2010-2012 (\$ MILLIONS)</i>	179
<i>FIGURE 33 BIO-RAD'S SALES HISTORY, 2010-2012 (\$ MILLIONS)</i>	179
CSL BEHRING	179
<i>TABLE 71 CSL LIMITED'S SALES HISTORY, 2010-2012 (\$ MILLIONS)</i>	180

TOPIC	PAGE NO.
<i>FIGURE 34 CSL LIMITED'S SALES HISTORY, 2010-2012 (\$ MILLIONS)</i>	180
ENTEGRION, INC.	180
GRIFOLS INTERNATIONAL, S.A./TALECRIS	181
<i>TABLE 72 GRIFOLS' SALES HISTORY, 2010-2012 (\$ MILLIONS)</i>	182
<i>FIGURE 35 GRIFOLS' SALES HISTORY, 2010-2012 (\$ MILLIONS)</i>	182
HAEMONETICS CORPORATION	183
<i>TABLE 73 HAEMONETICS' SALES HISTORY, 2010-2012 (\$ MILLIONS)</i>	183
<i>FIGURE 36 HAEMONETICS' SALES HISTORY 2010-2012 (\$ MILLIONS)</i>	183
HOLOGIC GEN-PROBE, INC.	184
<i>TABLE 74 HOLOGIC'S SALES HISTORY, 2010-2012 (\$ MILLIONS)</i>	185
<i>FIGURE 37 HOLOGIC'S SALES HISTORY 2010-2012 (\$ MILLIONS)</i>	185
NOVO NORDISK A/S	185
<i>TABLE 75 NOVO NORDISK'S SALES HISTORY, 2010-2012 (\$ MILLIONS)</i>	186
<i>FIGURE 38 NOVO NORDISK'S SALES HISTORY, 2010-2012 (\$ MILLIONS)</i>	186
OCTAPHARMA AG	187
<i>TABLE 76 OCTAPHARMA'S SALES HISTORY, 2010-2012 (\$ MILLIONS)</i>	187
<i>FIGURE 39 OCTAPHARMA'S SALES HISTORY, 2010-2012 (\$ MILLIONS)</i>	187
OMRIX BIOPHARMACEUTICALS, LTD.	188
<i>TABLE 77 JOHNSON & JOHNSON'S SALES HISTORY, 2010-2012 (\$ MILLIONS)</i>	189
<i>FIGURE 40 JOHNSON & JOHNSON'S SALES HISTORY, 2010-2012 (\$ MILLIONS)</i>	189
PFIZER, INC.	189
<i>TABLE 78 PFIZER'S SALES HISTORY, 2010-2012 (\$ MILLIONS)</i>	190
<i>FIGURE 41 PFIZER'S SALES HISTORY, 2010-2012 (\$ MILLIONS)</i>	190
ROCHE HOLDING LTD.	191
<i>TABLE 79 ROCHE'S SALES HISTORY, 2010-2012 (\$ MILLIONS)</i>	191
<i>FIGURE 42 ROCHE'S SALES HISTORY, 2010-2012 (\$ MILLIONS)</i>	191
CHAPTER 10 TECHNOLOGY	194
CLASSICAL FRACTIONATION METHODS	194
COHN FRACTIONATION	194
ADVANCED FRACTIONATION METHODS	194
AMPLIFICATION METHODS	195
POLYMERASE CHAIN REACTION (PCR)	195
NUCLEIC AMPLIFICATION TECHNOLOGY (NAT)	195
IMMUNOASSAY	195
ENZYME IMMUNOASSAY (EIA)	195
Basic EIA	196
<i>FIGURE 43 THE BASIC ENZYME IMMUNOASSAY (EIA) PROCESS</i>	196
Alternate EIA Methods	196
Second-Antibody Precipitation Method	196
Double-Antibody Sandwich Method	197
Reverse-Sandwich Method	197
Reverse-Sandwich Inhibition Method	197
CHAPTER 11 PATENT ANALYSIS	199
PATENT ANALYSIS	199
<i>TABLE 80 RECENTLY ISSUED PATENTS</i>	200

TOPIC	PAGE NO.
<i>TABLE 81 PATENTS BY COUNTRY OF ORIGIN</i>	200
<i>TABLE 82 RECENT PATENTS BY COMPANY</i>	201
FRESENIUS MEDICAL CARE	202
ORTHO-CLINICAL DIAGNOSTICS, INC.	202
ABBOTT LABORATORIES	202
CERNER INNOVATION, INC.	202
CHANGCHUN INSTITUTE OF APPLIED CHEMISTRY CHINESE ACADEMY OF SCIENCES	203
GELANUS B.V.	203
MICRONICS, INC.	203
TERUMO KABUSHIKI KAISHA	204
PATENT EXAMPLES	204
RECENT PATENTS	204
Blood Transfusions : Six Patents	204
Blood Bank : Three Patents	207
Blood Donor : Two Patents	208
CHAPTER 12 APPENDIX A GUIDANCE FOR INDUSTRY RECOGNITION AND USE OF A STANDARD FOR THE UNIFORM LABELING OF BLOOD AND BLOOD COMPONENTS	211
INTRODUCTION	211
REPORTING REQUIREMENTS FOR LICENSED ESTABLISHMENTS	211
FDA LICENSED ESTABLISHMENTS	211
CHAPTER 13 APPENDIX B MAJOR SOURCES OF INFORMATION	245
ABAXIS, INC.	245
ABBOTT LABORATORIES	245
ALBUMIN BIOSCIENCE	245
ALERE, INC.	245
ALFA SCIENTIFIC DESIGNS, INC.	245
AMERICAN RED CROSS	245
ARKRAY, INC.	246
ARYOGEN BIOPHARMA CO.	246
BAYER AG	246
BECKMAN COULTER, INC.	246
BECTON, DICKINSON, & CO.	246
BIOMERIEUX FRANCE	247
BIO-RAD LABORATORIES, INC.	247
BRISTOL-MYERS SQUIBB CO.	247
BTNX, INC.	247
CANGENE CORP.	247
CHARTER MEDICAL, LTD.	247
CHURCH & DWIGHT CO., INC.	248
CSL BEHRING	248
DANAHER CORP./RADIOMETER	248
ENTEGRION, INC.	248
FORA CARE, INC.	248
FUJIREBIO DIAGNOSTICS, INC.	248
GAMBRO INC.	249

TOPIC	PAGE NO.
G.E. HEALTHCARE LTD.	249
GLAXOSMITHKLINE PLC	249
GRIFOLS INTERNATIONAL, S.A.	249
GTC BIOTHERAPEUTICS/REVO BIOLOGICS	249
HAEMOTRONIC S.P.A.	250
HEMOCUE AB	250
HOLOGIC GEN-PROBE, INC.	250
IMMUCOR, INC.	250
INTERNATIONAL TECHNIDYNE CORP.	250
JANT PHARMACAL CORP.	250
JOHNSON & JOHNSON	251
KEDRION S.P.A	251
NATIONAL GENETICS INSTITUTE	251
NEXTRON MEDICAL TECHNOLOGIES	251
NIPRO DIAGNOSTICS, INC.	251
NOVA BIOMEDICAL CORP.	251
NOVARTIS AG	252
NOVO NORDISK A/S	252
NOVOZYMES BIOPHARMA, INC.	252
OCTAPHARMA AG	252
OMRIX BIOPHARMACEUTICALS, LTD.	252
OPK BIOTECH LLC	252
ORASURE TECHNOLOGIES, INC.	253
PALL CORP.	253
PFIZER, INC.	253
PHAMATECH, INC.	253
PRINCETON BIOMEDITECH CORPORATION	253
QUEST DIAGNOSTICS	253
QUIDEL CORP.	254
RESPONSE BIOMEDICAL CORP.	254
ROCHE	254
SA SCIENTIFIC, LTD.	254
SEKISUI DIAGNOSTICS	254
SIEMENS MEDICAL SOLUTIONS	255
SPECTRAL DIAGNOSTICS	255
STANBIO LABORATORY	255
TRINITY BIOTECH PLC	255
ZEUS SCIENTIFIC, INC.	255
CHAPTER 14 APPENDIX C GLOBAL BLOOD DONATION SOURCES	257
AMERICAN ASSOCIATION OF BLOOD BANKS	257
AMERICAN FRIENDS OF MAGEN DAVID ADOM	257
ARMED SERVICES BLOOD PROGRAM	257
ASSOCIATION OF VOLUNTARY ITALIAN BLOOD DONORS	257
AUSTRALIAN RED CROSS	257
CANADIAN BLOOD SERVICES	258
HEARTLAND BLOOD CENTERS	258

TOPIC	PAGE NO.
HONG KONG RED CROSS	258
INDIAN RED CROSS SOCIETY	258
IRISH NATIONAL BLOOD CENTRE	258
JAPANESE RED CROSS SOCIETY	258
NATIONAL BLOOD SERVICE	259
NEW ZEALAND BLOOD SERVICE	259
SOUTH AFRICAN NATIONAL BLOOD SERVICE	259
WORLD HEALTH ORGANIZATION	259

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL MARKET FOR BLOOD PRODUCTS, THROUGH 2017 (\$ MILLIONS)	7
TABLE 1 TIMELINE OF THE BLOOD INDUSTRY	13
TABLE 2 COMPOSITION OF BLOOD	16
TABLE 3 MAJOR DISEASES CONTRACTED FROM BLOOD TRANSFUSIONS, U.S. ANALYSIS	18
TABLE 4 CBER LICENSED HIV DONOR SCREENING TESTS (LAST UPDATED JANUARY 17, 2013)	21
TABLE 5 CBER LICENSED SCREENING TESTS FOR HEPATITIS B (LAST UPDATED JANUARY 17, 2013)	23
TABLE 6 CBER LICENSED SCREENING TESTS FOR HEPATITIS C (LAST UPDATED JANUARY 17, 2013)	24
TABLE 7 CBER LICENSED SCREENING TESTS FOR HTLV-I AND HTLV-II (LAST UPDATED JANUARY 17, 2013)	26
TABLE 8 CBER LICENSED SCREENING TESTS FOR CMV (LAST UPDATED JANUARY 17, 2013)	27
TABLE 9 CBER LICENSED SCREENING TESTS FOR WEST NILE (LAST UPDATED JANUARY 17, 2013)	28
TABLE 10 CBER LICENSED SCREENING TESTS FOR SYPHILIS (LAST UPDATED JANUARY 17, 2013)	29
TABLE 11 CBER LICENSED SCREENING TESTS FOR CHLAMYDIA (LAST UPDATED JANUARY 17, 2013)	32
TABLE 12 CBER LICENSED SCREENING TESTS FOR GONORRHEA (LAST UPDATED JANUARY 17, 2013)	33
TABLE 13 FDA REGISTERED BLOOD ESTABLISHMENTS BY STATE* AND POSSESSION	41
TABLE 14 ESTIMATED GLOBAL POPULATION AND GROWTH RATE BY SELECTED AGE GROUP AND SELECTED YEARS, THROUGH 2030 (MILLIONS)	46
TABLE 15 GLOBAL POPULATION BY SELECTED COUNTRY, THROUGH 2015 (MILLIONS)	47
TABLE 16 TESTS ROUTINELY PERFORMED ON BLOOD DONATIONS	53
TABLE 17 BLOOD TYPE ANTIGEN/ANTIBODY REACTIONS	54
TABLE 18 SELECTED USES OF FFP	60
TABLE 19 LISTING OF BLOOD PRODUCTS FOR THERAPEUTIC USE	61
TABLE 20 FACTORS TO REDUCE RISKS OF TRANSFUSION- ASSOCIATED DISEASES	71
TABLE 21 TRANSFUSION-RELATED FATALITIES BY COMPLICATION, FY 2008-FY 2012	73
TABLE 22 FATALITIES NOT RELATED TO TRANSFUSION OR TRANSFUSION NOT RULED OUT, FY2008-FY2012	74
TABLE 23 POST-DONATION "NOT RULED OUT" FATALITY REPORTS BY DONATED PRODUCT, FY2008 THROUGH FY2012	74
TABLE 24 FEDERAL ORGANIZATIONS RESPONSIBLE FOR U.S. BLOOD SAFETY	76
TABLE 25 FDA AUTHORITY IN REGULATING BLOOD BANKING AND BLOOD PRODUCTS	79
TABLE 26 MAJOR AREAS OF CONCERN FOR INSPECTING BLOOD FACILITIES	83
TABLE 27 ESTIMATED U.S. COST OF BLOOD COMPONENTS, THROUGH 2012 (\$)	94
TABLE 28 U.S. BLOOD COLLECTION AND TRANSFUSION DATA, THROUGH 2017 (MILLION UNITS/PINTS)	109
TABLE 29 PLASMA COLLECTIONS FOR THE U.S. AND OTHER MARKETS, THROUGH 2017 (\$ BILLIONS, MILLIONS ML)	110
TABLE 30 PLASMA PRODUCTS MARKET FOR THE U.S. AND OTHER MARKETS,* THROUGH 2017 (\$ BILLIONS)	111
TABLE 31 GLOBAL MARKET SIZE OF PLASMA THERAPEUTIC DERIVATIVES BY TYPE, THROUGH 2017 (\$ MILLIONS)	112

TABLE HEADING	PAGE NO.
TABLE 32 CURRENTLY MARKETED ALBUMIN AND PLASMA PROTEIN FRACTION (PPF) PRODUCTS (%)	115
TABLE 33 GLOBAL MARKET FOR HUMAN SERUM ALBUMIN AND PPF BY REGION, THROUGH 2017 (\$ MILLIONS)	116
TABLE 34 EXAMPLES OF COMMON BLOOD CLOTTING FACTORS	118
TABLE 35 WORLDWIDE AND U.S. HEMOPHILIA STATISTICS, 2012 ESTIMATES	120
TABLE 36 GLOBAL MARKET FOR PLASMA-DERIVED AND RECOMBINANT CLOTTING FACTORS, THROUGH 2017 (REVENUES IN \$ MILLIONS)	120
TABLE 37 GLOBAL MARKET FOR PLASMA-DERIVED AND RECOMBINANT CLOTTING FACTORS BY REGION, THROUGH 2017 (\$ MILLIONS)	121
TABLE 38 FDA APPROVED FACTOR VIII PRODUCTS	122
TABLE 39 GLOBAL MARKET SHARE OF FACTOR VIII COMPANIES, 2012	125
TABLE 40 FDA APPROVED FACTOR IX PRODUCTS	126
TABLE 41 GLOBAL MARKET SHARE OF FACTOR IX COMPANIES, 2012 (%/MILLIONS)	127
TABLE 42 FDA APPROVED FACTOR VII PRODUCTS	128
TABLE 43 GLOBAL MARKET SHARE OF FACTOR IX COMPANIES, 2012 (PERCENT/MILLIONS)	129
TABLE 44 FDA APPROVED PROTHROMBIN COMPLEX CONCENTRATE PRODUCTS	130
TABLE 45 SELECTED CONDITIONS TREATED BY IVIG	131
TABLE 46 FDA APPROVED IMMUNOGLOBULINS	132
TABLE 47 FDA APPROVED HYPERIMMUNE IMMUNOGLOBULINS	133
TABLE 48 GLOBAL MARKET FOR IMMUNOGLOBULINS, THROUGH 2017 (\$ MILLIONS)	136
TABLE 49 GLOBAL MARKET FOR IMMUNOGLOBULINS BY REGION, THROUGH 2017 (\$ MILLIONS)	136
TABLE 50 GLOBAL MARKET FOR FIBRIN SEALANTS AND THROMBIN, THROUGH 2017 (\$ MILLIONS)	140
TABLE 51 GLOBAL MARKET FOR FIBRIN SEALANTS AND THROMBIN BY REGION, THROUGH 2017 (\$ MILLIONS)	141
TABLE 52 GLOBAL MARKET FOR ANTITHROMBIN, THROUGH 2017 (\$ MILLIONS)	143
TABLE 53 GLOBAL MARKET FOR ANTITHROMBIN BY REGION, THROUGH 2017 (\$ MILLIONS)	143
TABLE 54 GLOBAL MARKETS FOR BLOOD TYPING AND SCREENING PRODUCTS, THROUGH 2017 (\$ MILLIONS)	144
TABLE 55 GLOBAL MARKETS FOR BLOOD TYPING AND SCREENING PRODUCTS, THROUGH 2017 (\$ MILLIONS)	146
TABLE 56 SELECTED PCR DONOR SCREENING TESTS	147
TABLE 57 SELECTED NAT DONOR SCREENING TESTS	148
TABLE 58 SELECTED IMMUNOASSAY DONOR SCREENING TESTS	149
TABLE 59 THE GLOBAL BLOOD DONOR SCREENING TESTING MARKET BY TYPE OF TESTS, THROUGH 2017 (\$ MILLIONS)	150
TABLE 60 SELECTED SUPPLIERS: MAJOR DONOR SCREENING TEST AREAS	151
TABLE 61 THE GLOBAL MARKET FOR BLOOD TYPING INSTRUMENTS AND SUPPLIES BY TYPE, THROUGH 2017 (\$ MILLIONS)	153
TABLE 62 GLOBAL MARKET FOR BLOOD COLLECTION AND PROCESSING EQUIPMENT AND CONSUMABLES, THROUGH 2017 (\$ MILLIONS)	156
TABLE 63 GLOBAL MARKET FOR BLOOD AND PLASMA COLLECTION AND TRANSFUSION PRODUCTS, THROUGH 2017 (\$ MILLIONS)	158
TABLE 64 GLOBAL MARKET FOR COLLECTION PRODUCTS BY TYPE, THROUGH 2017 (\$ MILLIONS)	159
TABLE 65 GLOBAL MARKET FOR TRANSFUSION PRODUCTS BY TYPE, THROUGH 2017 (\$ MILLIONS)	164

TABLE HEADING	PAGE NO.
TABLE 66 REGIONAL VETERINARY BLOOD BANKS	171
TABLE 67 ABBOTT'S SALES HISTORY, 2010-2012 (\$ MILLIONS)	175
TABLE 68 BAXTER'S SALES HISTORY, 2010-2012 (\$ MILLIONS)	176
TABLE 69 BAYER'S SALES HISTORY, 2010-2012 (\$ MILLIONS)	177
TABLE 70 BIO-RAD'S SALES HISTORY, 2010-2012 (\$ MILLIONS)	179
TABLE 71 CSL LIMITED'S SALES HISTORY, 2010-2012 (\$ MILLIONS)	180
TABLE 72 GRIFOLS' SALES HISTORY, 2010-2012 (\$ MILLIONS)	182
TABLE 73 HAEMONETICS' SALES HISTORY, 2010-2012 (\$ MILLIONS)	183
TABLE 74 HOLOGIC'S SALES HISTORY, 2010-2012 (\$ MILLIONS)	185
TABLE 75 NOVO NORDISK'S SALES HISTORY, 2010-2012 (\$ MILLIONS)	186
TABLE 76 OCTAPHARMA'S SALES HISTORY, 2010-2012 (\$ MILLIONS)	187
TABLE 77 JOHNSON & JOHNSON'S SALES HISTORY, 2010-2012 (\$ MILLIONS)	189
TABLE 78 PFIZER'S SALES HISTORY, 2010-2012 (\$ MILLIONS)	190
TABLE 79 ROCHE'S SALES HISTORY, 2010-2012 (\$ MILLIONS)	191
TABLE 80 RECENTLY ISSUED PATENTS	200
TABLE 81 PATENTS BY COUNTRY OF ORIGIN	200
TABLE 82 RECENT PATENTS BY COMPANY	201

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL MARKET FOR BLOOD PRODUCTS, 2010-2017 (\$ MILLIONS)	7
FIGURE 1 ESTIMATED GLOBAL POPULATION BY SELECTED AGE GROUP AND SELECTED YEARS, 2000-2030 (MILLIONS)	46
FIGURE 2 GLOBAL POPULATION BY SELECTED COUNTRY, 2010 AND 2015 (MILLIONS)	47
FIGURE 3 VARIABLES INFLUENCING THE DYNAMICS OF DEMAND FOR BLOOD FOR TRANSFUSION	91
FIGURE 4 BLOOD MARKET COST AND PRICING ANALYSIS	92
FIGURE 5 U.S. BLOOD COLLECTION AND TRANSFUSION DATA, 2007-2017 (MILLION UNITS/PINTS)	109
FIGURE 6 PLASMA COLLECTIONS FOR THE U.S. AND OTHER MARKETS, 2010-2017 (MILLION ML)	110
FIGURE 7 PLASMA PRODUCTS MARKET FOR THE U.S. AND OTHER MARKETS,* 2010-2017 (\$ BILLIONS)	111
FIGURE 8 GLOBAL MARKET SIZE OF PLASMA THERAPEUTIC DERIVATIVES BY TYPE, 2010-2017 (MILLIONS)	112
FIGURE 9 GLOBAL MARKET FOR HUMAN SERUM ALBUMIN AND PPF BY REGION, 2010-2017 (MILLIONS)	116
FIGURE 10 GLOBAL MARKET FOR PLASMA-DERIVED AND RECOMBINANT CLOTTING FACTORS, 2010-2017 (\$ MILLIONS)	121
FIGURE 11 GLOBAL MARKET FOR PLASMA-DERIVED AND RECOMBINANT CLOTTING FACTORS BY REGION, 2010-2017 (MILLIONS)	121
FIGURE 12 GLOBAL MARKET SHARE OF FACTOR VIII COMPANIES, 2012 (%)	125
FIGURE 13 GLOBAL MARKET SHARE OF FACTOR VIII BY HUMAN AND RECOMBINANT PRODUCTS, 2012 (%)	125
FIGURE 14 GLOBAL MARKET SHARE OF FACTOR IX COMPANIES, 2012 (%)	127
FIGURE 15 GLOBAL MARKET SHARE OF FACTOR IX COMPANIES, 2012 (%)	129
FIGURE 16 GLOBAL MARKET FOR IMMUNOGLOBULINS, 2010-2017 (MILLIONS)	136
FIGURE 17 GLOBAL MARKET FOR IMMUNOGLOBULINS BY REGION, THROUGH 2017 (\$ MILLIONS)	137
FIGURE 18 GLOBAL MARKET FOR FIBRIN SEALANTS AND THROMBIN, 2010-2017 (\$ MILLIONS)	141
FIGURE 19 GLOBAL MARKET FOR FIBRIN SEALANTS AND THROMBIN BY REGION, 2010-2017 (\$ MILLIONS)	142
FIGURE 20 GLOBAL MARKET FOR ANTITHROMBIN, 2010-2017 (\$ MILLIONS)	143
FIGURE 21 GLOBAL MARKET FOR ANTITHROMBIN BY REGION, 2010-2017 (\$ MILLIONS)	143
FIGURE 22 GLOBAL MARKETS FOR BLOOD TYPING AND SCREENING PRODUCTS, 2010-2017 (\$ MILLIONS)	144
FIGURE 23 GLOBAL MARKETS FOR BLOOD TYPING AND SCREENING PRODUCTS, 2010-2017 (\$ MILLIONS)	146
FIGURE 24 GLOBAL BLOOD DONOR SCREENING TESTING MARKET BY TYPE, 2010-2017 (\$ MILLIONS)	150
FIGURE 25 THE GLOBAL MARKET FOR BLOOD TYPING INSTRUMENTS AND SUPPLIES BY TYPE, 2010-2017 (\$ MILLIONS)	153
FIGURE 26 GLOBAL MARKET FOR BLOOD COLLECTION AND PROCESSING EQUIPMENT AND CONSUMABLES, 2010-2017 (\$ MILLIONS)	156
FIGURE 27 GLOBAL MARKET FOR BLOOD AND PLASMA COLLECTION AND TRANSFUSION PRODUCTS, 2010-2017 (\$ MILLIONS)	158
FIGURE 28 GLOBAL MARKET FOR COLLECTION PRODUCTS BY TYPE, 2010-2017 (\$ MILLIONS)	159

FIGURE TITLE	PAGE NO.
FIGURE 29 GLOBAL MARKET FOR TRANSFUSION PRODUCTS BY TYPE, 2010-2017 (\$ MILLIONS)	164
FIGURE 30 ABBOTT'S SALES HISTORY, 2010-2012 (\$ MILLIONS)	175
FIGURE 31 BAXTER'S SALES HISTORY, 2010-2012 (\$ MILLIONS)	176
FIGURE 32 BAYER'S SALES HISTORY, 2010-2012 (\$ MILLIONS)	177
FIGURE 33 BIO-RAD'S SALES HISTORY, 2010-2012 (\$ MILLIONS)	179
FIGURE 34 CSL LIMITED'S SALES HISTORY, 2010-2012 (\$ MILLIONS)	180
FIGURE 35 GRIFOLS' SALES HISTORY, 2010-2012 (\$ MILLIONS)	182
FIGURE 36 HAEMONETICS' SALES HISTORY 2010-2012 (\$ MILLIONS)	183
FIGURE 37 HOLOGIC'S SALES HISTORY 2010-2012 (\$ MILLIONS)	185
FIGURE 38 NOVO NORDISK'S SALES HISTORY, 2010-2012 (\$ MILLIONS)	186
FIGURE 39 OCTAPHARMA'S SALES HISTORY, 2010-2012 (\$ MILLIONS)	187
FIGURE 40 JOHNSON & JOHNSON'S SALES HISTORY, 2010-2012 (\$ MILLIONS)	189
FIGURE 41 PFIZER'S SALES HISTORY, 2010-2012 (\$ MILLIONS)	190
FIGURE 42 ROCHE'S SALES HISTORY, 2010-2012 (\$ MILLIONS)	191
FIGURE 43 THE BASIC ENZYME IMMUNOASSAY (EIA) PROCESS	196